title: Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.
abstract: OBJECTIVE
  The prognosis of glioblastoma multiforme (GBM) remains poor despite advances in surgery and adjuvant therapies. TP53 and O6-methylguanine-DNA methyltransferase (MGM) are tumor suppressor genes that are implicated in GBM resistance to radiation and chemotherapy. In order to assess the expression of the protein products of these two genes, 50 GBM samples were analyzed in this study.
  
  
  METHODS
  Demographic and clinical data along with postsurgery tumor samples from 50 GBM patients were collected from the pathology archive. MGMT and p53 protein expression was evaluated by immunohistochemistry.
  
  
  RESULTS
  52% of cases had mutated p53, predominantly expressed in the nuclei of tumor cells. MGMT immunohistochemistry was negative in 35 (70%) patients and positive in 15 (30%) others. Immunohistochemistry-negative specimens for MGMT expression showed a significantly higher expression of mutant p53 (P = 0.03).
  
  
  CONCLUSIONS
  MGMT expression was significantly lower in cells bearing p53 mutation. This indicates that there is a tendency for p53 activity to decline with MGMT inactivation. However, this study could not deduce which protein was the regulator of the other.
authors.affiliation: Department of Biochemistry, Payame Nour University Mashhad, Iran.
authors.forename: Marziyeh
authors.initials: M
authors.lastname: Lotfi
authors.forename: Sima
authors.initials: S
authors.lastname: Afsharnezhad
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Raziee
authors.forename: Kamran
authors.initials: K
authors.lastname: Ghaffarzadegan
authors.forename: Samaneh
authors.initials: S
authors.lastname: Sharif
authors.forename: Jamal
authors.initials: J
authors.lastname: Shamsara
authors.forename: Sara
authors.initials: S
authors.lastname: Lary
authors.forename: Javad
authors.initials: J
authors.lastname: Behravan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000201:enzymology* / Q000208:ethnology / Q000235:genetics*; D015254:DNA Modification Methylases / Q000378:metabolism*; D045643:DNA Repair Enzymes / Q000378:metabolism*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000201:enzymology* / Q000208:ethnology / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D007492:Iran / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes